TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* has HCV RNA ≥10,000 IU/mL in peripheral blood at the time of screening~* has documented chronic HCV GT1 or GT3 infection~* has either negative or positive history of liver cirrhosis based on liver biopsy, Fibroscan, or FibroSure ® (Fibrotest®)~* is treatment naïve to all anti-HCV treatment~Exclusion Criteria:~* has evidence of decompensated liver disease~* is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or human immunodeficiency virus~* has a history of malignancy ≤5 years prior to signing informed consent, or is under evaluation for other active or suspected malignancy~* has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* has clinically-relevant drug or alcohol abuse within 12 months of screening~* has any of the following conditions: organ transplants other than cornea and hair, poor venous access that precludes routine peripheral blood sampling, history of gastric surgery or malabsorption disorders, or any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* has a history of chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GT1:NC Grazoprevir/Elbasvir+SOF 4wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
- GT1:NC Grazoprevir/Elbasvir+SOF 6wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
- GT1:C Grazoprevir/Elbasvir+SOF 6wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
- GT1:C Grazoprevir/Elbasvir+SOF 8wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
- GT3:NC Grazoprevir/Elbasvir+SOF 8wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
- GT3:NC Grazoprevir/Elbasvir+SOF 12wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
- GT3:C Grazoprevir/Elbasvir+SOF 12wk (Type: EXPERIMENTAL): Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-in-human Evaluation of [18F]CETO

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with adrenal incidentalomas with an concurrent overproduction of aldosterone or cortisol or no concurrent hormone production, or patients diagnosed with adrenocortical carcinoma~* For healthy volunteers inclusion criteria included no known diseases, no ongoing medication and no known adrenal anomalies.~Exclusion Criteria for patients and healthy volunteers:~* pregnancy, age below 18, claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- First-in-man investigastion of [18F]CETO (Type: EXPERIMENTAL): 15 patients were investigated with PET/CT after injection of 2,5 MBq/kg \[18F\]CETO. 5 healthy volunteers were investigated twice (Test-retest), with approximately 2 weeks in-between each PET/CT investigation, after injection of 1,3 MBq/kg \[18F\]CETO. Arterial blood samples were taken as well as urinary sampels.~3 out of 5 healthy volunteers were also investigated twice with PET/CT after injection of 13,2 MBq/kg \[15O\]water, performed before the \[18F\]CETO PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Criteria:~* Pathologically confirmed newly diagnosed acute myeloid leukemia (AML)~* Subtypes M0, M1, M2, M4-7 disease~* No newly diagnosed acute promyelocytic leukemia (M3)~* Any of the following diseases:~* De novo disease~* Secondary AML~* Myelodysplasia (MDS)-related AML (MDS/AML)~* Treatment-related AML~* Previously untreated disease~* Patients who have received prior hydroxyurea alone or non-cytotoxic therapies for MDS (e.g., thalidomide, interferon, cytokines, 5-azacytidine, or revlimid) will be eligible for this study~* Must be considered ineligible for traditional antileukemia chemotherapy~* No hyperleukocytosis with ≥ 30,000 blasts/uL or rapidly rising blast count with projected doubling time of =\< 2 days~* Patients may receive hydroxyurea to lower blast count to \< 30,000 blasts/uL up to 24 hours before beginning tipifarnib and etoposide~* No active CNS leukemia~* No prior tipifarnib or etoposide~* No concurrent radiotherapy, immunotherapy, or other chemotherapy~* No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, fosphenytoin, phenobarbital, primidone, carbamazepine, or oxcarbazepine)~* Patients may be changed to non-enzyme-inducing anticonvulsants and stabilized before starting study treatment~Inclusion Criteria:~* ECOG performance status 0-2~* Serum creatinine =\< 2.0 mg/dL~* SGOT and SGPT =\< 3 times upper limit of normal~* Bilirubin =\< 2 mg/dL~Exclusion Criteria:~* Active, uncontrolled infection~* Patients with infection under active treatment and controlled with antimicrobials are eligible~* Presence of other life-threatening illnesses~* Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol~* Allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, or econazole)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
- Arm II (closed to accrual as of November 2008) (Type: EXPERIMENTAL): Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Sleep in Veterans and Their CGs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Care recipient must be age 60 and over and require assistance from the identified caregiver with more than one Activity of Daily Living or three or more Instrumental Activities of Daily Living,~* have a life expectancy of greater than or equal to six (6) months,~* have no plans for transitioning out of home in the next six months,~* and have approval from the primary care provider to participate in the research.~* Caregivers must live with care recipient~* Caregivers must obtain a negative mini-cog assessment or negative TICS-m assessment. Caregivers can be any relation (spouse, child, sibling, friend, etc.) to the care recipient so long as the two are cohabitating.~* Caregiver can be any age.~* For Phase 2 and Phase 3 of the study, either the care recipient or the caregiver must have difficulty sleeping as indicated by scores on the Insomnia Severity Index.~Exclusion Criteria:~* Parkinson's with tremor or other movement disorder that would invalidate actigraphy~* Untreated diagnosis of sleep apnea or restless leg syndrome~* Inability to tolerate actigraphy~* CG and CR sleep efficiency \> 85% and/or both members of dyad report sleeping well~* Caregivers must have a negative screen with the Mini-Cog or the ModifiedTelephone Interview for Cognitive Status (TICS-M) to demonstrate cognitive capacity to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SLEEP-E Dyads Intervention (Type: EXPERIMENTAL): SLEEP-E Dyads Six-Week Tele-Health Intervention~1. . Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~2. . Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~3. . Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~4. . SLEEP-E Dyads book~5. . Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching
- Usual Care Group (Type: NO_INTERVENTION): During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)~* Age \>1 year and \< less than 18 years old~* Induction chemotherapy ≤ 14 days according to institutional standard of care~* Adequate liver, renal and cardiac function~Exclusion Criteria:~* Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor~* Extramedullary involvement of the testicles~* Active systemic bacterial, fungal or viral infection~* Down syndrome

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Dasatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease~* History of at least one unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Diabetes mellitus~* Change in body weight greater than 5 kg within 3 months prior to starting study~* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity~* History of pancreatitis~* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed\* grade 1, 2, or 3 follicular B-cell non-Hodgkin lymphoma meeting the following criteria:~  * Bulky stage II or stage III or IV disease~ * Diffuse large cell component must be \< 25% of the biopsy~ * Confirmed cluster of differentiation antigen 20 (CD20) antigen-positive disease NOTE: \*Needle aspiration or cytology are not considered adequate for pathology review~* Patient must have unilateral or bilateral bone marrow aspirate and biopsy performed within 42 days~  * Positive biopsy performed \> 42 days but \< 6 months allowed~* Previously untreated disease~* Bidimensionally measurable disease~* No clinical evidence of central nervous system (CNS) involvement by lymphoma~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-2~* Cardiac ejection fraction ≥ 45% by multigated acquisition scan (MUGA) or ECHO~* No significant cardiac abnormalities~* No known HIV positivity~* No requirement for continuous supplemental oxygen therapy~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer from which the patient is currently in complete remission~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of maintenance therapy~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, radiotherapy, or antibody therapy for lymphoma~* No prior solid organ transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-CHOP, tositumomab and rituximab (Type: EXPERIMENTAL): Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven locally advanced squamous cell carcinoma of the head and neck Stage III or IV without distant metastases Unresectable Primary tumor sites: Oral cavity Oropharynx Hypopharynx Larynx Must have at least one measurable lesion~PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT and SGPT no greater than 2.5 times ULN Alkaline phosphatase no greater than 5 times ULN No SGOT and SGPT greater than 1.5 times ULN AND alkaline phosphatase greater than 2.5 times ULN Renal: Creatinine no greater than 1.4 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: At least 6 months since prior myocardial infarction No unstable, treated cardiac disease Pulmonary: At least one year since prior hospitalization for chronic obstructive pulmonary disease Neurologic: No neurologic or psychiatric disorders (e.g., dementia or seizures) No concurrent peripheral neuropathy greater than grade 1 Other: No active uncontrolled infection No active peptic ulcer No alteration in hearing At least 5 years since any other neoplastic disease except curatively treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or other cancer curatively treated by surgery Not pregnant or nursing Fertile patients must use effective contraception No other psychological, familial, sociological, or geographical condition that would prevent compliance~PRIOR CONCURRENT THERAPY: Biologic therapy: No primary prophylactic colony stimulating factors during the first course of therapy Chemotherapy: No prior or concurrent chemotherapy Endocrine therapy: At least 3 weeks since prior corticosteroid No chronic corticosteroid therapy (greater than 3 months) Radiotherapy: No prior radiotherapy Surgery: No prior surgery for this cancer Other: At least 30 days since prior treatment in a clinical trial No concurrent use of drugs that interact with fluorouracil (e.g., cimetidine, allopurinol, folic acid or leucovorin calcium) No other concurrent investigational drugs or anticancer treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ulcerative colitis for greater than/equal to 3 months.~* Moderate to severe active ulcerative colitis~* Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.~Exclusion Criteria:~* Pregnant or breastfeeding~* Clinical findings suggestive of Crohn's Disease~* History of bowel surgery within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06651600 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06651600 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06651600 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06651600 Placebo (Type: PLACEBO_COMPARATOR): Delivered orally for 8 weeks.
- PF-06700841 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 8 weeks
- PF-06700841 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06700841 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 8 weeks.
- PF-06700841 Placebo (Type: PLACEBO_COMPARATOR): Delivered orally for 8 weeks.
- PF-06651600 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 24 weeks.
- PF-06700841 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ONO-7436 Phase II Study in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients age 20 years or older~2. Patients with malignant tumor who are to be intravenously administered cisplatin as a single dose of 70 mg/m2 or more in under 3 hours~3. Patients whose performance status is 0 to 2~4. Other inclusion criteria as specified in the study protocol~Exclusion Criteria:~1. In case of patients who are previously treated with cisplatin, those having no past history of vomiting as of administration of cisplatin~2. Patients who had vomiting or dry vomiting within 24 hours before the initial administration of the moderate or severe emetic chemotherapy (including cisplatin) on Day 1 of the study~3. Pregnant women, nursing women, women of child-bearing potential, women who wish to become pregnant or women using oral contraception~4. Other exclusion criteria as specified in the study protocol

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete